Trodelvy
Total Payments
$24.0M
Transactions
28,480
Doctors
7,541
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10.6M | 4,656 | 1,501 |
| 2023 | $6.5M | 10,529 | 4,417 |
| 2022 | $2.2M | 9,503 | 3,996 |
| 2021 | $2.1M | 3,197 | 1,759 |
| 2020 | $2.5M | 595 | 288 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.7M | 1,902 | 65.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.8M | 1,505 | 19.9% |
| Consulting Fee | $1.7M | 623 | 7.2% |
| Travel and Lodging | $967,142 | 2,164 | 4.0% |
| Food and Beverage | $753,521 | 21,644 | 3.1% |
| Education | $55,864 | 637 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $14,550 | 5 | 0.1% |
Payments by Type
Research
$15.7M
1,902 transactions
General
$8.3M
26,578 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | Gilead Sciences, Inc. | $3.2M | 0 |
| Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens | Gilead Sciences, Inc. | $1.7M | 0 |
| Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer | Gilead Sciences, Inc. | $1.7M | 0 |
| A phase 2 study of response-guided neoadjuvant Sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer | Gilead Sciences, Inc. | $1.4M | 0 |
| SATEEN: A single-arm phase II trial of SAcituzumab govitecan and Trastuzumab after progrEssion on Enhertu | Gilead Sciences, Inc. | $1.1M | 0 |
| IMMU-132-05 | Immunomedics, Inc. | $839,249 | 0 |
| IMMU-132-09 | Immunomedics, Inc. | $783,688 | 1 |
| A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physican's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) | Gilead Sciences, Inc. | $650,899 | 0 |
| IMMU132-2020-043 / 20-0102 A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma | Gilead Sciences, Inc. | $475,256 | 0 |
| Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers | Gilead Sciences, Inc. | $407,241 | 0 |
| A phase II evaluation of Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, in patients with persistent or recurrent endometrial carcinoma | Gilead Sciences, Inc. | $401,000 | 0 |
| A Phase II Open-Label Study of Sacituzumab govitecan in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | Gilead Sciences, Inc. | $383,614 | 0 |
| SERIES: Sequencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW MetaStatic Breast Cancer | Gilead Sciences, Inc. | $342,494 | 0 |
| A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer | Gilead Sciences, Inc. | $297,337 | 0 |
| IMMU-132-06 | Immunomedics, Inc. | $247,067 | 0 |
| Sacituzumab govitecan in combination with cisplatin in platinum sensitive recurrent ovarian and endometrial cancer | Gilead Sciences, Inc. | $240,512 | 0 |
| A phase II evaluation of Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate in recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers | Gilead Sciences, Inc. | $240,088 | 0 |
| A phase 2 study of sacituzumab govitecan with or without anti-PD/ PD-L1 checkpoint inhibitor immunotherapy in small cell bladder, adenocarcinoma of the bladder, squamous cell bladder/urinary tract cancer, renal medullary carcinoma and penile cancer | Gilead Sciences, Inc. | $196,500 | 0 |
| A phase II study of neoadjuvant sacituzumab and pembrolizumab therapy for pembrolizumab and cytotoxic chemotherapy-resistant primary triple-negative breast cancer | Gilead Sciences, Inc. | $174,468 | 0 |
| IMMU-132 | Immunomedics, Inc. | $162,337 | 0 |
Top Doctors Receiving Payments for Trodelvy — Page 302
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , PA | Physician Assistant | Troy, MI | $11.66 | 1 |
| Muhammad Hameed | Student in an Organized Health Care Education/Training Program | Kalamazoo, MI | $11.66 | 1 |
| , M.D | Hematology & Oncology | Fayetteville, AR | $11.64 | 1 |
| , M.D | Hematology & Oncology | Rogers, AR | $11.64 | 1 |
| , NP | Adult Health | New York, NY | $11.64 | 1 |
| , APRN | Family | Fayetteville, AR | $11.64 | 1 |
| , MD | Hematology & Oncology | Belleville, NJ | $11.61 | 1 |
| , MD | Hematology & Oncology | Bakersfield, CA | $11.59 | 1 |
| , M.D | Hematology & Oncology | Wichita, KS | $11.55 | 1 |
| , MD | Hematology & Oncology | Troy, OH | $11.50 | 1 |
| , MD, PHD | Hematology & Oncology | Monterey, CA | $11.42 | 1 |
| , NP | Family | Candor, NY | $11.14 | 1 |
| Prakash Patel | — | Portsmouth, OH | $11.08 | 1 |
| , FNP-BC | Family | Seaman, OH | $11.08 | 1 |
| , M.D | Hematology & Oncology | Arroyo Grande, CA | $10.53 | 1 |
| , MD | Internal Medicine | Fort Worth, TX | $6.67 | 1 |
| , M.D. PH.D | Internal Medicine | Dallas, TX | $4.34 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $21.5M
- Immunomedics, Inc. $2.5M
Product Information
- Type Drug
- Total Payments $24.0M
- Total Doctors 7,541
- Transactions 28,480
About Trodelvy
Trodelvy is a drug associated with $24.0M in payments to 7,541 healthcare providers, recorded across 28,480 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences, Inc..
Payment data is available from 2020 to 2024. In 2024, $10.6M was paid across 4,656 transactions to 1,501 doctors.
The most common payment nature for Trodelvy is "Unspecified" ($15.7M, 65.4% of total).
Trodelvy is associated with 20 research studies, including "Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy" ($3.2M).